Recombinant Anti-Bora antibody [EPR11610] (ab182149)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR11610] to Bora
- Suitable for: WB, ICC/IF, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Bora antibody [EPR11610]
See all Bora primary antibodies -
Description
Rabbit monoclonal [EPR11610] to Bora -
Host species
Rabbit -
Tested applications
Suitable for: WB, ICC/IF, IPmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human fetal brain, HeLa and Jurkat whole cell lysate (ab7899); HeLa cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR11610 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab182149 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 70 kDa (predicted molecular weight: 61 kDa).
|
|
ICC/IF |
1/100 - 1/250.
|
|
IP |
1/40.
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 70 kDa (predicted molecular weight: 61 kDa). |
ICC/IF
1/100 - 1/250. |
IP
1/40. |
Target
-
Function
Required for the activation of Aurora-A (AURKA/STK6) at the onset of mitosis. -
Sequence similarities
Belongs to the BORA family. -
Post-translational
modificationsPhosphorylated by AURKA/STK6. - Information by UniProt
-
Database links
- Entrez Gene: 79866 Human
- Entrez Gene: 77744 Mouse
- Entrez Gene: 306102 Rat
- Omim: 610510 Human
- SwissProt: Q6PGQ7 Human
- SwissProt: Q8BS90 Mouse
- SwissProt: Q5M864 Rat
- Unigene: 643464 Human
see all -
Alternative names
- Aurora borealis antibody
- bora antibody
- bora, aurora kinase A activator antibody
see all
Images
-
All lanes : Anti-Bora antibody [EPR11610] (ab182149) at 1/10000 dilution
Lane 1 : Human fetal brain tissue lysate
Lane 2 : HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 61 kDa -
Immunofluorescent analysis of HeLa cells (-20℃ Acetone-fixed) labeling Bora with ab182149 at 1/250 dilution followed by Goat anti rabbit IgG (Alexa Fluor® 488) secondary at 1/200 diution.
-
Anti-Bora antibody [EPR11610] (ab182149) at 1/10000 dilution + Jurkat cell lysate at 10 µg
Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 61 kDa -
Western blot analysis of immunoprecipitation pellet from HeLa cell lysate immunoprecipitated using ab182149 at 1/40 dilution.
Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (1)
ab182149 has been referenced in 1 publication.
- Tian Y et al. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol 12:67 (2019). PubMed: 31253167